Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

ESR1 mutation + HR positive

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

›

ESR1 mutation + HR positive	HER2 Negative Breast Cancer	ESR1 mutation + HR positive	HER2 Negative Breast Cancer	elacestrant Sensitive: A2 - Guideline ASCO.org - 3 weeks (New A2) elacestrant Sensitive : A2 ASCO.org - 3wk	elacestrant Sensitive: A2 - Guideline ASCO.org - 3 weeks elacestrant Sensitive : A2 ASCO.org - 3 weeks - (New A2)
ESR1 mutation + HR positive	HER2 Negative Breast Cancer	ESR1 mutation + HR positive	HER2 Negative Breast Cancer	everolimus Sensitive: A2 - Guideline ASCO.org - 3 weeks (New A2) everolimus Sensitive : A2 ASCO.org - 3wk	everolimus Sensitive: A2 - Guideline ASCO.org - 3 weeks everolimus Sensitive : A2 ASCO.org - 3 weeks - (New A2)
ESR1 mutation + HR positive	HER2 Negative Breast Cancer	ESR1 mutation + HR positive	HER2 Negative Breast Cancer	tamoxifen Sensitive: A2 - Guideline ASCO.org - 3 weeks (New A2) tamoxifen Sensitive : A2 ASCO.org - 3wk	tamoxifen Sensitive: A2 - Guideline ASCO.org - 3 weeks tamoxifen Sensitive : A2 ASCO.org - 3 weeks - (New A2)
ESR1 mutation + HR positive	HER2 Negative Breast Cancer	ESR1 mutation + HR positive	HER2 Negative Breast Cancer	Aromatase inhibitor Sensitive: A2 - Guideline ASCO.org - 3 weeks (New A2) Aromatase inhibitor Sensitive : A2 ASCO.org - 3wk	Aromatase inhibitor Sensitive: A2 - Guideline ASCO.org - 3 weeks Aromatase inhibitor Sensitive : A2 ASCO.org - 3 weeks - (New A2)
ESR1 mutation + HR positive	HER2 Negative Breast Cancer	ESR1 mutation + HR positive	HER2 Negative Breast Cancer	fulvestrant Sensitive: A2 - Guideline ASCO.org - 3 weeks (New A2) fulvestrant Sensitive : A2 ASCO.org - 3wk	fulvestrant Sensitive: A2 - Guideline ASCO.org - 3 weeks fulvestrant Sensitive : A2 ASCO.org - 3 weeks - (New A2)
ESR1 mutation + HR positive	HER2 Negative Breast Cancer	ESR1 mutation + HR positive	HER2 Negative Breast Cancer	palbociclib Sensitive: B - Late Trials palbociclib Sensitive : B	palbociclib Sensitive: B - Late Trials palbociclib Sensitive : B